NCT02095145View on ClinicalTrials.gov

Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 8, 2014

Primary Completion Date

January 23, 2018

Study Completion Date

September 26, 2019

Conditions

PSA Level Less Than or Equal to FifteenPSA Level Less Than TenStage I Prostate Cancer AJCC v7Stage II Prostate Cancer AJCC v7Stage IIA Prostate Cancer AJCC v7Stage IIB Prostate Cancer AJCC v7

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

OTHER

Placebo

Given PO

DRUG

Pomegranate-Extract Pill

Given PO

Trial Locations (4)

53792

University of Wisconsin Hospital and Clinics, Madison

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

78229

Urology San Antonio Research PA, San Antonio

01805

Lahey Hospital and Medical Center, Burlington

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT02095145 - Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance | Biotech Hunter | Biotech Hunter